IBA Boston Consulting Group Matrix

IBA's 'Other Accelerators' segment, which includes industrial and radiopharma solutions, demonstrated robust growth in 2024. Revenue saw an 18% jump, while order intake surged by an impressive 43%.

These solutions are positioned for sustained expansion, particularly in the industrial sterilization market, which is expected to grow at a compound annual growth rate exceeding 10%. This indicates that these offerings are becoming increasingly significant contributors to IBA's overall business.

The company's ability to convert its backlog and secure strategic contracts further solidifies the strong market position and upward growth trajectory of its industrial and radiopharma accelerators.

IBA's proton therapy solutions, particularly the Proteus®ONE system, are firmly positioned as Stars in the BCG matrix due to their high market share and the rapidly expanding proton therapy market. As of Q1 2025, 30 Proteus®ONE units are installed across 38 global projects, showcasing IBA's market leadership.

The company's dominance is further evidenced by its capture of 60% of all proton therapy systems sold globally in 2024. This segment is projected to grow at a CAGR of 13.30% between 2025 and 2034, indicating sustained high growth potential for IBA's offerings.

IBA's strategic focus on making proton therapy more accessible and cost-effective through systems like Proteus®ONE is a key factor in maintaining this Star status. This approach broadens the market and reinforces IBA's strong position in a field experiencing increasing demand for advanced cancer treatments.

IBA's industrial sterilization base, particularly its established solutions with a long operational history, likely commands a significant market share within a mature segment of the industrial applications market. These offerings are expected to generate consistent, predictable revenue streams from their existing installed base and associated service contracts, necessitating reduced promotional investment due to their proven reliability and market acceptance.

These robust cash flows from the industrial sterilization segment are crucial for funding research and development initiatives in IBA's higher-growth business areas, ensuring continued innovation and market expansion. For instance, in 2023, IBA reported that its Sterilization segment contributed significantly to its overall revenue, with specific figures often highlighting steady performance despite market maturity.

IBA's established dosimetry solutions are a cornerstone of their business, firmly positioned as a Cash Cow within the BCG matrix. This segment operates in the mature market for radiation therapy quality assurance, where IBA holds a significant market share.

Despite experiencing flat revenue growth in 2024, this stability is precisely what makes it a Cash Cow. The consistent cash flow generated from these robust quality assurance products is vital, providing the necessary financial fuel to invest in and drive growth in other, more dynamic areas of IBA's portfolio.

IBA's leadership in dosimetry is well-established, evidenced by their strong reputation and the reliability of their offerings. This mature segment's predictable performance underpins the company's overall financial strategy, enabling innovation and expansion elsewhere.

Certain regional sales or service offerings for mature products may consistently underperform. This underperformance often stems from intense local competition or a lack of market adoption, even when the product itself is successful globally. For instance, a company might find its established product line showing only a 3% market share in a specific region with a projected 2% annual growth rate.

These geographical segments, characterized by low market share and low growth, risk becoming cash traps if not managed proactively. If not addressed, these underperforming areas could drain resources without yielding significant returns. IBA's overarching global strategy is designed to identify and minimize such regional underperformances to optimize resource allocation.

Dogs in the IBA BCG Matrix represent products with low market share and low market growth, often characterized by declining demand or technological obsolescence. These are typically offerings that IBA has strategically decided to phase out, as they consume resources without generating substantial returns. Identifying and managing these products is crucial for optimizing resource allocation and focusing on growth areas.

For instance, a legacy product line with minimal regional penetration, such as a specific type of industrial accelerator used in a niche, shrinking market, would fit this category. In early 2024, market analyses indicated that such niche industrial segments could see annual declines of around 3%, making them prime candidates for the Dog classification. These products often require ongoing investment for maintenance or compliance, potentially leading to negative cash flow, as seen in a hypothetical 2023 scenario where a product line incurred $250,000 in operational costs against $150,000 in revenue.

The strategic imperative for IBA is to reallocate capital from these underperforming Dogs to more promising Stars or Cash Cows. This divestment or phasing out of products with market irrelevance, low demand, or technological obsolescence allows for a leaner business structure and ensures investments align with long-term strategic objectives. Companies in 2024 continued to prune portfolios, with reports suggesting that the semiconductor industry alone discontinued an estimated 5-10% of its product SKUs due to market shifts.

IBA's investment in PanTera, a joint venture aimed at boosting Actinium-225 (Ac-225) production for radiopharmaceuticals, clearly fits the Question Mark category in the BCG matrix. This is because PanTera is operating in a rapidly expanding market for targeted radionuclide therapies, a sector experiencing significant growth and innovation.

Despite the high-growth potential of the radiopharmaceutical market, PanTera, as a relatively new venture, currently holds a low market share. This characteristic is typical of Question Marks, which are in developing markets but haven't yet established a dominant position.

PanTera requires substantial cash investment for its development and scaling efforts, particularly to address the critical global shortage of Ac-225. The success of this venture hinges on its ability to overcome production challenges and secure a significant portion of the market, potentially transforming it into a Star performer in the future.

Question Marks in IBA's portfolio represent areas with high growth potential but currently low market share. These are often new technologies or markets where significant investment is required to establish a foothold. Success in these areas could lead to future Stars, but there's also a risk of them becoming Dogs if they fail to gain traction.

IBA's DynamicARC® proton arc therapy, ConformalFLASH® Flash Therapy, and its investment in PanTera for Actinium-225 production are prime examples of Question Marks. These ventures are in rapidly expanding sectors like advanced proton therapy and radiopharmaceuticals, but they are still in early development or have not yet achieved significant market penetration.

The success of these Question Marks hinges on substantial R&D investment, regulatory approvals, and aggressive market development. For instance, the radiopharmaceutical market's projected growth to over USD 14 billion by 2030 highlights the potential, but current market share for specific accelerators in niche applications remains modest.

Electron beam technology's application in environmental remediation, particularly for PFAS, also falls into this category. While the market for PFAS remediation is expected to grow substantially, IBA's current share is low, necessitating significant investment to validate efficacy and capture emerging opportunities.